人口的药理动力学,剂量优化和临床结果的biapenem在患有败血症的患者
Dayu Chen1,2, Xuanyu Wu1,2,3, Haixia Zhang4
1Department of Pharmacy, Nanjing Drum Tower Hospital, Nanjing, China.
Frontiers in pharmacology
|May 27, 2024
概括
治疗败血症的biapenem剂量需要优化. 一种种群的药理动力学模型表明,每6小时服用600毫克可能比目前的每日1.2克剂量更有效,以实现败血症患者的治疗目标.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
- 关键护理医学 关键护理医学
背景情况:
- 比亚胺是一种卡巴胺抗生素,用于细菌感染.
- 在败血症群体中对biapenem的药理动力学数据有限.
- 在败血症中优化双胺疗法至关重要.
研究的目的:
- 为了评估在败血症患者中biapenem的药理动力学.
- 为了建立一个人群的药理动力学 (PPK) 模型用于sepsis中的biapenem.
- 为了确定最佳的biapenem剂量,以获得有利的临床结果.
主要方法:
- 使用了人口药理动力学 (PPK) 方法.
- 用NONMEM软件分析了来自317名败血症患者的数据.
- 共变量分析确定了肌素清除和血液尿素作为重要因素.
主要成果:
- 一个两部分的PPK模型最好地描述了双胺的药理动力学.
- 肌素清除影响了双胺清除,BUN影响了区间间清除.
- 达到70%的时间自由药物度超过MIC (fT>MIC) 与积极的结果有关.
结论:
- 开发了一个PPK模型用于败血症中的biapenem.
- 目前的每日1.2克剂量可能对败血症患者来说不足.
- 建议每6小时服用600毫克的剂量方案是最优的.
相关概念视频
Biopharmaceutics and Pharmacokinetics: Overview
2.0K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.0K
Analysis of Population Pharmacokinetic Data
252
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
252
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
60
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
60
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
156
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
156
Combined Effects of Drugs: Synergism
3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.9K
Pneumonia IV: Management
322
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
322


